Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
Yuan Cheng, Newbury Park, CA (US); Chawita Netirojjanakul, Longmont, CO (US); Jerry Ryan Holder, Simi Valley, CA (US); Bin Wu, Thousand Oaks, CA (US); James R. Falsey, Moorpark, CA (US); Bradley J. Herberich, Newbury Park, CA (US); Kelvin Sham, Thousand Oaks, CA (US); Leslie P. Miranda, Thousand Oaks, CA (US); Shu-Chen Lu, Thousand Oaks, CA (US); Murielle M. Venient-Ellison, Thousand Oaks, CA (US); Shanaka Stanislaus, Thousand Oaks, CA (US); Junming Yie, Warren, NJ (US); and Jing Xu, Waltham, MA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Jan. 15, 2021, as Appl. No. 17/151,045.
Application 17/151,045 is a division of application No. 15/872,841, filed on Jan. 16, 2018, granted, now 10,905,772.
Claims priority of provisional application 62/447,332, filed on Jan. 17, 2017.
Prior Publication US 2021/0154318 A1, May 27, 2021
1. A method of treating a subject with a metabolic disorder, the method comprising administering to the subject a composition comprising a monoclonal human antibody that specifically binds to a polypeptide comprising the extracellular N-terminus of human Gastric Inhibitory Peptide Receptor (“GIPR”), wherein the antibody comprises a cysteine amino acid at one or more conjugation site(s); and a Glucagon Like Polypeptide-1 (“GLP-1”) receptor agonist, wherein the GLP-1 receptor agonist is conjugated to the antibody through the side-chain of the cysteine amino acid at the one or more conjugation site(s).